Astellas’ Xtandi cleared in Japan for prostate cancer treatment

24 March 2014

Japanese drug major Astellas Pharma (TSE: 4503) has obtained the marketing approval in Japan of its oral androgen receptor signaling inhibitor Xtandi (enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan.

Astellas filed an application for approval in Japan in May 2013. Xtandi, which is being jointly developed and commercialized with US-based company, Medivation (Nasdaq: MDVN), obtained approval in August 2012 in the USA and in June 2013 in Europe for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously received docetaxel (chemotherapy).

On receiving this marketing authorization in Japan, Astellas will provide Medivation with a $15 million milestone payment, the company said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK